Aptorum Group Limited - Class A Ordinary Shares (APM)
1.5500
-0.0100 (-0.64%)
NASDAQ · Last Trade: Nov 19th, 11:49 AM EST
Detailed Quote
Previous Close
1.560
Open
1.570
Bid
1.540
Ask
1.560
Day's Range
1.530 - 1.590
52 Week Range
0.4600 - 4.800
Volume
109,508
Market Cap
5.97M
PE Ratio (TTM)
-4.559
EPS (TTM)
-0.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
102,962
Chart
About Aptorum Group Limited - Class A Ordinary Shares (APM)
Aptorum Group Ltd is a biotechnology and pharmaceutical company focused on developing innovative therapeutic solutions to address significant unmet medical needs. The company is involved in the discovery and commercialization of new drugs, particularly in the areas of metabolic diseases, infectious diseases, and other major health challenges. Aptorum Group is dedicated to advancing its proprietary drug candidates through various stages of development, including preclinical and clinical trials, while also exploring strategic partnerships and collaborations to enhance its research capabilities and market reach. Read More
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp.
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconference/).
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Aptorum Group Limited (NASDAQ: APM) shares dropped 33.18% in Friday's pre-market trading after soaring 234.65% the previous session, driven by DiamiR's test approval and merger news, with trading volume far above average.
